TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02946021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head and neck garments for pneumatic compression device
Description: Pneumatic compression device cleared for use by patients who are under medical supervision for the treatment of 1) lymphedema (primary or secondary); 2) edema resulting from mastectomies, trauma, sports injuries or post immobilization; 3) venous insufficiencies; 4) wounds; and 5) stasis dermatitis, venous stasis ulcers, arterial leg ulcers and diabetic foot ulcers and treatment of head and neck lymphedema

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head and neck garments for pneumatic compression device
Description: Pneumatic compression device cleared for use by patients who are under medical supervision for the treatment of 1) lymphedema (primary or secondary); 2) edema resulting from mastectomies, trauma, sports injuries or post immobilization; 3) venous insufficiencies; 4) wounds; and 5) stasis dermatitis, venous stasis ulcers, arterial leg ulcers and diabetic foot ulcers and treatment of head and neck lymphedema

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIRFLI with ICG
Description: Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic movement in subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIRFLI with ICG
Description: Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic movement in subjects.
Study: NCT01954199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurodynamic Group
Description: All techniques will be executed in a pain-free way (grade III). Mild discomfort will be accepted, but it must subside as soon as the technique ends.~* In the dynamic opener technique, patient will be positioned in side-lying, with the affected side upwards. The therapist will then perform grade III oscillations aiming to open the lumbar foramen;~* In the side-lying slider, the patient will be in side-lying with the affected side upwards. A combination of knee and hip flexion and extension movements will produce sliding in the neural structures;~* In the slump slider, the patient will be seated in slump position. Combinations between neck and knee movements will produce greater nerve excursion than the side-lying slider. Patients will perform the slump slider in a pain-free manner.
Study: NCT02578888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy + idiographic
Description: Ancillary studies
Study: NCT01729845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study: NCT00890890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avagacestat
Description: Capsules, Oral, 50 mg, once daily, 104 - 220 Weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 104 - 220 Weeks
Study: NCT02460055

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal tube
Description: This study will determine if the placement of an ETT will lead to dysphagia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol 3mg/kg will be administered to facilitate endotracheal intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol 3mg/kg will be administered to facilitate endotracheal intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 0.15mg/kg up to 20 mg will be used for anti-emesis prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 0.15mg/kg up to 20 mg will be used for anti-emesis prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron 0.15mg/kg up to 4mg will be used for anti-emesis prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron 0.15mg/kg up to 4mg will be used for anti-emesis prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane, nitrous oxide and oxygen
Description: Inhalational agents will be used to induce general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane, nitrous oxide and oxygen
Description: Inhalational agents will be used to induce general anesthesia
Study: NCT04565262

Intervention type: DRUG
Group type: OTHER
Intervention: NAs+IFN-α
Description: NAs+IFN-α:(NAs +IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96 weeks。 NAs+(NAs+IFN-α) :NAs/48weeks+(NAs+ IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）for 48 weeks ，then combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96weeks。 Response guided treatment（RGT） by HBsAg quantification： The course of interferon alpha was 24 weeks after HBsAg and HBeAg turned negative up to 96 weeks, and NAs was discontinued 12 months after HBsAg serological conversion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAs+IFN-α
Description: NAs+IFN-α:(NAs +IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96 weeks。 NAs+(NAs+IFN-α) :NAs/48weeks+(NAs+ IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）for 48 weeks ，then combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96weeks。 Response guided treatment（RGT） by HBsAg quantification： The course of interferon alpha was 24 weeks after HBsAg and HBeAg turned negative up to 96 weeks, and NAs was discontinued 12 months after HBsAg serological conversion.
Study: NCT02080546

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cut-Coag
Description: Incision using electrothermal cautery, with an attempt made to use the cut (continuous low-voltage, high-current) for colpotomy incision following the initial scoring of the cervico-vaginal tissue on the coag (pulsed high-voltage, low-current) mode.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: V-mode
Description: Incision using electrothermal cautery in the V mode. The V mode combines real-time tissue sensing technology with the cut and coag waveforms to reduce the amount of thermal spread to the tissue without sacrificing hemostasis during monopolar electrothermal procedures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Valleylab G3000 Electrosurgical Device
Description: Use of surgical device Valleylab G3000 Electrosurgical Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valleylab G3000 Electrosurgical Device
Description: Use of surgical device Valleylab G3000 Electrosurgical Device
Study: NCT00104767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study: NCT00844597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-4658 for Injection
Description: AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-4658 for Injection
Description: AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-4658 for Injection
Description: AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-4658 for Injection
Description: AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-4658 for Injection
Description: AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-4658 for Injection
Description: AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
Study: NCT01931982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victoza
Study: NCT00550212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272, Single-dose capsule and solution
Study: NCT02392104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.
Study: NCT02581059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginseng
Description: Subjects randomized to ginseng will receive 1,000 mg orally twice every day of each 28-day cycle for 2 cycles.
Study: NCT01299311

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NEAT
Description: 4 days of everyday activities, including 4 hours of walking, 8 hours of sitting, 2 hours of standing, 2 hours of everyday activities and 8 hours of sleeping or laying down per day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 4 days of activity program, including 1 hour biking (exercise), 13 hours of sitting, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
Study: NCT01963169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TO-BoneHealth Program (Bone Power Program)
Description: The 8-week TO-BoneHealth program include: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TO-BoneHealth Plus Program (Bone Power Plus Program)
Description: This intervention includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
Study: NCT00665093

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
Study: NCT01183247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Add rapamycin de novo to tacrolimus and MMF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Add everolimus de novo to tacrolimus and MMF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Add prednisone de novo to tacrolimus and MMF
Study: NCT01262092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buprenorphine
Description: Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
Study: NCT03510767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3525
Description: TQ-B3525 p.o. qd
Study: NCT04182347

Intervention type: OTHER
Group type: OTHER
Intervention: Health Research ToolKit Development
Description: The Toolkit will be an accessible, structured process for people with IDD and people with IDD's paid and unpaid caregivers to be engaged partners. Learning activities are focused on leadership, information about research, health for individuals with IDD. Learning activities will include topics:~What is health research? What is the health research process? How can individuals with IDD be involved in health research? Where is research happening? How to think like a researcher. Creating health stories for research and care advocacy.~The learning activities will teach individuals with IDD information and allow participants to practice the learning.
Study: NCT01386723

Intervention type: DRUG
Intervention: Discontinuation of eltrombopag
Description: Observation of subjects as they discontinue the use of eltrombopag
Study: NCT02994771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lymfactin® [1 x 10E10 vp]
Description: Lymfactin® \[1 x 10E10 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lymfactin® [1 x 10E11 vp]
Description: Lymfactin® \[1 x 10E11 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.
Study: NCT04565002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Diaphragmatic Stimulation
Description: The procedure consists of electrical stimulation in the region of the motor points of the diaphragm. Its configurations contribute to produce involuntary muscle contractions. There are four electrodes positioned superficially on the skin.
Study: NCT03506347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Antibiotic
Study: NCT01554722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle placement
Description: In plane versus out of plane needle placement techniques

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle placement
Description: In plane versus out of plane needle placement techniques
Study: NCT00794170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone and Print based intervention
Description: Thiss intervention consisted of tailored phone calls and follow-up mailings.
Study: NCT01030718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID
Study: NCT01474629

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic-based dietary supplement
Description: 24 trained men receive a probiotic-based dietary supplement for 16 weeks. Dosage 3x 10-9 per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 24 trained men receive a placebo for 16 weeks with same dosage compared to active group
Study: NCT03214536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block
Description: bilateral injection of local anaesthetic between the erector spinae muscle and the transverse process

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: injection of 20 ml ropivacaine 0.375 % bilateral by erector spinae block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spine surgery
Description: Surgery of lumbar spine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthesia
Description: general anesthesia
Study: NCT01249508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition label
Study: NCT01294059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: 50 mg BID Oral x 6 Weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Milnacipran
Description: 50 mg BID Oral x 6 Weeks
Study: NCT00099632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate
Description: 200mg/300mg as one tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate
Description: 200mg/300mg as one tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/Zidovudine
Description: 150mg/300mg as one tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/Zidovudine
Description: 150mg/300mg as one tablet taken orally twice daily
Study: NCT02772237

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin 400mg daily

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01937026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Administered orally
Study: NCT02984254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Womac
Description: Answer Womac questionnaires at baseline, 1 month, 3 months and 1 year

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Womac
Description: Answer Womac questionnaires at baseline, 1 month, 3 months and 1 year

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lequesne
Description: Answer Lequesne questionnaires at baseline, 1 month, 3 months and 1 year

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lequesne
Description: Answer Lequesne questionnaires at baseline, 1 month, 3 months and 1 year

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Timed-up-and-go (TUG)
Description: Perform Timed-up-and-go (TUG) at baseline, 1 month, 3 months and 1 year

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Timed-up-and-go (TUG)
Description: Perform Timed-up-and-go (TUG) at baseline, 1 month, 3 months and 1 year

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: five-times-sit-to-stand-test (FTSST)
Description: Perform the five-times-sit-to-stand-test (FTSST) at baseline, 1 month, 3 months and 1 year
Study: NCT00099632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: 133.3mg/33.3mg as three capsules taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: 133.3mg/33.3mg as three capsules taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose Nevirapine
Description: one 200 mg tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose Nevirapine
Description: one 200 mg tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose Nevirapine
Description: one 200 mg tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose Nevirapine
Description: one 200 mg tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose Nevirapine
Description: one 200 mg tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose Nevirapine
Description: one 200 mg tablet taken orally
Study: NCT03240185

Intervention type: BEHAVIORAL
Intervention: deep breathing exercises
Description: Patients receive education on deep breathing exercises for pain control as part of their pre-operative appointment
Study: NCT03236116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Description: Participants will consume almonds everyday for 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (no nuts)
Description: Participants will not be permited to consume any nuts for 6 months.
Study: NCT01638195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: Focused Ultrasound
Study: NCT03811054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib（250mg/d） combined with EGFR-TKI
Description: Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
Study: NCT02984254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: five-times-sit-to-stand-test (FTSST)
Description: Perform the five-times-sit-to-stand-test (FTSST) at baseline, 1 month, 3 months and 1 year

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Six-minute walk test.
Description: Perform six-minute walk test at baseline, 3 months and 1 year

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Six-minute walk test.
Description: Perform six-minute walk test at baseline, 3 months and 1 year

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional patellofemoral neoprene brace
Description: Use the functional patellofemoral neoprene brace for 2 hours/day minimum - 12 hours/day maximum

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neoprene sleeve brace.
Description: Use the neoprene sleeve brace for 2 hours/day minimum - 12 hours/day maximum